Concise Drug Review: Pazopanib and Axitinib

Pazopanib and axitinib are both U.S. Food and Drug Administration approved ATP-competitive inhibitors of the vascular endothelial growth factor receptor. Pazopanib and axitinib have been shown to be effective and tolerable treatment options for patients with metastatic renal cell cancer and therefor...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: van Geel, Robin M.J.M., Beijnen, Jos H., Schellens, Jan H.M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AlphaMed Press 2012
Konular:
New Drug Development and Clinical Pharmacology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3425526/
https://ncbi.nlm.nih.gov/pubmed/22733795
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0055
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller